Dynamic42 and EPO Collaborate to Enhance Glioblastoma Research with Organ-on-Chip Technology
Dynamic42 and Experimental Pharmacology and Oncology (EPO), both based in Germany, have announced a strategic collaboration to address the limited availability of preclinical models in brain cancer research. The partnership aims to integrate organ-on-chip technologies into preclinical drug development, focusing on glioblastoma and the blood-brain barrier (BBB). By combining Dynamic42's organ-on-chip platforms with EPO's expertise in translational oncology, the collaboration seeks to develop experimental setups that more accurately reflect human tumor biology. This approach is expected to generate data that translates more reliably into clinical outcomes, potentially improving therapeutic responses and reducing late-stage failure risks in drug development. 
